ANGLE Targets A Rich CTC Niche In Liquid Biopsy

14 Mar 2016

A multibillion-dollar market is on the way for liquid biopsy, which allows the measurement of markers present in biological fluids, a repeatable method of disease diagnosis that could replace some invasive biopsies and allow clinicians access to tissues that have been inaccessible with current methods. Within this dynamic field, ANGLE PLC is coming closer to clinical application market readiness with its circulating tumor cell harvesting technology, as CEO Andrew Newland explains.

In our annual review of the diagnostics industry, we identified liquid biopsy as one of the big stories of 2015. Investors have flocked to the space and Roche, the market leader in molecular diagnostics, was just one of many companies that expanded its presence in the field through acquisitions or strategic alliances last year. (See Also see "Diagnostics In 2015: Past Trends Coalesce, New Roads Open" - In Vivo, 21 January, 2016..) The timing couldn't be better for ANGLE PLC, which has been developing its liquid biopsy technology for a decade and is building toward clinical commercial launch.

Originally an IP commercialization specialist, ANGLE saw the potential in a cell isolation technology invented by Philadelphia scientist George Hvichia,...